Learn more ACCEPT HOME STRATEGIES SECTORS ABOUT US CAREERS MEDIA OUR SECTORS A bronze statue of OSIRIS, Egypt, 1075–716 BC. His disciples consumed the psychedelic substance DMT. We aspire to be thought leaders in frontier technology. With our investments, we strive to create the world we want to live in. BACKING A BETTER FUTURE Life Sciences DISCOVER FinTech & Crypto DISCOVER Future Tech DISCOVER LIFE SCIENCES Christian’s first successful investment/foundation, at the age of 20, was Ribopharma; which later merged with a US company and today is stock-market-listed Alnylam Pharmaceuticals (ticker symbol ALNY, US$ 23bn market cap). Hence, we have a special interest in and passion for biotech. Many of today’s global mega-trends, such as our aging population, create a continuously rising demand for new and innovative medical devices and drugs. Our main focus is on longevity & mental wellbeing. We want to enable people to live longer, healthier and happier lives. Apeiron’s platform company atai Life Sciences (NASDAQ: ATAI) is making significant headway towards unlocking innovative treatments to improve the status quo for the more than 1 billion people worldwide who are suffering from mental health issues, including depression, anxiety, addiction, and post-traumatic stress disorder. atai currently has multiple projects underway to investigate the potential of psychedelic compounds like “magic mushrooms” / psilocybin, DMT (N-Dimethyltryptamine) and ibogaine, and establish these as approved medical treatments. Apeiron’s platform companies REJUVERON and CAMBRIAN develop medical drugs and technologies which have the potential to significantly prolong human lifespan. We firmly believe that we will see advances within the next 10-30 years which will push a healthy human lifespan towards several hundred years, including the ability to rejuvenate and turn back the signs of aging. Aging is a disease, and we will cure it. FINTECH & CRYPTO Merging our profound experience at the nexus of traditional financial services and technology, we are one of the most active and influential investors in European FinTech, InsurTech, PropTech and crypto-related companies. We have a particular focus on crypto-currencies and blockchain-related business models. Apeiron’s cryptocurrency investments are mainly run via our stock market listed platform company Cryptology Asset Group (German exchange, CAP:GR), the largest dedicated crypto investor in Europe. Cryptology is the largest institutional investor in Block.One, the company which created the protocol token EOS and the crypto exchange BULLISH. Block.One is one of the largest known owners of Bitcoin globally, holding >170k Bitcoins. FUTURE TECH Life has never been more exciting. Over the next 20 years, we as the human race will not just completely redesign the world around us – from synthetic biology to self-driving cars to space travel, to just name a few examples – but also re-design and re-define what it means to be human itself. We will slow down and one day even reverse aging and extend healthy human life span way beyond 100 years. But is a finite life experience part of what makes us human? We will have therapeutics not just preventing Alzheimer’s and Dementia, but also increasing the intellectual capacity in young people. How will upgraded human intellects view themselves? Advances in AI, Quantum Computing and synthetic biology will create leapfrogs throughout any sector. But how will a sentient AI define its own existence versus the human race? And these are just a few examples. Every single aspect of our life will be fundamentally touched and transformed by technology over the next 20 years. And we want to be the driving force of this exciting time and help create the world we want to live in and help design the next human agenda. HOME STRATEGIES SECTORS ABOUT US CAREERS MEDIA CONTACT Apeiron Investment Group Ltd. Beatrice, at 66 & 67 Amery Street SLM1707 Sliema Malta JOIN OUR MAILING LIST Sign up to receive the latest news on Apeiron Group: SUBSCRIBE Privacy & Cookie Policy Terms & Conditions © 2021 Apeiron Investment Group Ltd. All Rights Reserved